SPC Financial Inc. lowered its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 22.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,163 shares of the company's stock after selling 3,560 shares during the period. SPC Financial Inc.'s holdings in Johnson & Johnson were worth $1,858,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently added to or reduced their stakes in the company. CWM LLC lifted its position in Johnson & Johnson by 4.7% in the second quarter. CWM LLC now owns 539,187 shares of the company's stock valued at $82,361,000 after purchasing an additional 24,269 shares during the period. Advocate Group LLC increased its holdings in Johnson & Johnson by 4.8% in the second quarter. Advocate Group LLC now owns 68,504 shares of the company's stock valued at $10,464,000 after buying an additional 3,137 shares in the last quarter. Wealth Advisory Team LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $236,000. Franklin Parlapiano Turner & Welch LLC increased its holdings in Johnson & Johnson by 1.3% in the second quarter. Franklin Parlapiano Turner & Welch LLC now owns 50,531 shares of the company's stock valued at $7,719,000 after buying an additional 641 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in Johnson & Johnson by 13.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 267,704 shares of the company's stock valued at $40,999,000 after buying an additional 31,553 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
Analyst Ratings Changes
JNJ has been the subject of a number of research analyst reports. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $209.00 target price on shares of Johnson & Johnson in a report on Friday. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the company an "overweight" rating in a report on Friday, October 3rd. Morgan Stanley increased their target price on shares of Johnson & Johnson from $176.00 to $178.00 and gave the company an "equal weight" rating in a report on Friday, October 10th. UBS Group increased their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a report on Monday, October 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $193.88.
Get Our Latest Stock Analysis on JNJ
Johnson & Johnson Trading Down 0.0%
Shares of JNJ opened at $190.88 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a 50 day simple moving average of $179.28 and a 200-day simple moving average of $164.16. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40. The stock has a market cap of $459.70 billion, a price-to-earnings ratio of 20.41, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson's payout ratio is presently 55.61%.
Insider Buying and Selling
In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.16% of the company's stock.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.